Risk factors of fatal outcome in patients with COVID-19 pneumonia

Michaela Cellina¹, MD (0000-0002-7401-1971), Daniele Gibelli², MD, PhD, Carlo Valenti Pittino³, MD, Tahereh Toluian³, MD, Pietro Marino⁴, MD, Giancarlo Oliva¹, MD

1. Department of Radiology
ASST Fatebenefratelli Sacco
Piazza Principessa Clotilde 3, 20121, Milano, Italy
2. Dipartimento di Scienze Biomediche per la Salute
Università degli Studi di Milano
Via Mangiagalli 31, 20133, Milano, Italy
3. Scuola di Specializzazione in Radiodiagnostica
Università degli Studi di Milano
Via Festa del Perdono 7, 20122, Milano, Italy
4. Department of Emergency Medicine
ASST Fatebenefratelli Sacco
Piazza Principessa Clotilde 3, 20121, Milano, Italy

Corresponding author:
Michaela Cellina
michaela.cellina@asst-fbf-sacco.it
ASST Fatebenefratelli Sacco, Milano
Piazza Principessa Clotilde 3, 20121, Milano, Italy
Authors declare no conflict of interest.
Abstract

Aim:
To correlate the clinical, laboratory, and radiographic characteristics of patients with a confirmed diagnosis of COVID-19 disease, with fatal outcome.

Methods:
We reviewed Chest X-Ray (CXR) features, clinical, and laboratory data of patients with RT-PCR confirmed diagnosis of COVID-19 infection. The relationship with mortality was investigated by fitting a logistic regression model.

Results:
246 patients were included (170 males; mean age: 63). Most of the patients had one or more comorbidity (62%); fever (95%) and cough (60%) were the most common symptoms; CXR detected abnormalities in 88.6%, mainly showing ground-glass opacities (GGO) (90 %) with bilateral (64%) and peripheral (46%) distribution.

Multivariate analysis showed that age (p<.001; mortality of 59% in patients >66 years old; 5% at a younger age) and consolidation at CXR (p=.001; mortality of 11% with positive CXR; 2% in those without) represented the two most significant independent risk factors of mortality. Chronic pathologies such as diabetes and chronic obstructive pulmonary disease and peripheral GGO at CXR also showed a significant correlation with mortality.

Conclusions:
We identified predictive factors for the fatal outcome of COVID-19 patients. The prognostic value of these findings can be useful for the right patient management and resource allocation.

Keywords: Pneumonia, Viral; Patient Outcome Assessment; COVID-19; coronavirus disease; Radiography
1. Introduction

Several cases of pneumonia of unknown etiology have been reported in Wuhan City, Hubei Province, China, in December 2019 [1]. The virus causing the epidemic was identified on Jan 7 as a new coronavirus (2019-nCoV), and the resulting pneumonia was named by the WHO as Coronavirus Disease 2019 (COVID-19) [2]. As of August 31, 2020, a total of 25,118,689 confirmed cases and of 844,312 deaths have been reported worldwide [3]. Clinical manifestations of COVID-19 infection are highly variable: serious cases develop severe pneumonia, ARDS, and multiple organ failures leading to death, non-severe cases present ordinary symptoms of respiratory system infection, and asymptomatic cases have also been reported [2, 4-7].

One of the issues the involved countries are facing is represented by the very high volume of patients presenting to health centers or hospitals during the outbreak, that overwhelms the healthcare resources available, especially the need for critical care support. Early and effective predictors of clinical outcomes are urgently needed for risk stratification of COVID-19 patients, to help effective patient management and resource allocation [8, 9]. Therefore, our aim was to retrospectively analyze clinical, laboratory, and radiographic characteristics of a consecutive series of patients who presented to our Emergency Department with symptoms suspected for COVID-19 infection, with confirmed diagnosis at real-time reverse transcriptase polymerase-chain-reaction (RT-PCR), to assess the correlation with fatal outcome, to identify variables with prognostic value.

2. Materials and Methods

This single-center retrospective study was approved by our IRB and performed in a hospital with about 60,000 annual Emergency Department accesses, located in the center of Milan, in Northern Italy, an area heavily hit by the COVID-19 outbreak. Consent was obtained from
the patients involved: after confirmation of COVID-19 positivity, the patients were asked to provide consent regarding the use of anonymized demographic and clinical information and submission to the experimental treatments.

All clinical, laboratory and outcome data were extracted from electronic medical records using a standardized data collection form.

2.1 Patients

We retrospectively analyzed data from our hospital Emergency Department electronic database of consecutive patients who presented to our Emergency Department with symptoms suspected of COVID-19 infections from 15 February to 30 March 2020. Inclusion criteria were as follows: 1) patients aged more than 18 years, as our Hospital was converted in a COVID-19 hub for adults, whereas pediatric patients were treated in other designated Institutions; 2) COVID-19 diagnosis confirmation through RT-PCR test performed using nasal and rhinopharyngeal swab specimens; 3) availability of chest X-Ray and laboratory blood tests executed at patient arrival, and of clinical (symptoms and comorbidities) data assessed at patient admission; 4) patient discharged or deceased. The clinical outcomes of recovery or death were monitored up to April 30th, 2020, the final date of follow-up.

2.2 Clinical data

All data were collected in a standardized excel electronic database; the variables to insert were decided in consensus by an emergency physician and a radiologist in a preliminary meeting, mainly based only upon our clinical practical experience.

Clinical data and radiological images collection was performed by two radiology residents in consensus, blinded to the aim of the study, trained in previous research studies. Data recording was made under the supervision of a radiologist, who checked the correctness of the information.
Patients with missing data were excluded from the analysis. Weekly meetings were held between all study participants to check the progress of data collection.

The following comorbidities were investigated from patients’ history: diabetes, arterial hypertension, chronic obstructive pulmonary disease, asthma, cardiovascular disease, cardiac failure, atrial fibrillation, stroke, dementia, obesity, chronic renal insufficiency, malignancy, HIV infection (according to the patients’ characteristics collected by the Epidemiology for Public Health-Istituto Superiore di Sanità [10]. The assumption of Angiotensin-converting enzyme inhibitors (ACEi) was recorded, as ACE2 has been shown to be a co-receptor for viral entry for SARS-CoV-2, with increasing evidence of its role in the pathogenesis of COVID-19, and a concern that the use of ACEI increases expression of ACE2 and patient susceptibility to viral host cell entry and propagation [11,12].

We collected patients’ symptoms as follows: cough, dyspnea, hemoptysis, chest pain, cutaneous rash, gastrointestinal symptoms, conjunctivitis, fever, and days of fever. Temperature and oxygen saturation at patient arrival were collected, as well as patients' treatments and days of hospitalization.

2.3 Blood tests

We collected the following blood tests, according to the protocol adopted for suspected COVID-19 patients in our clinical practice, and to the agreement between the emergency physician and the radiologist who decided the variables to collect: Leukocytes, Neutrophils, Lymphocytes, Platelets, Erythrocytes, D-dimer, Aspartate aminotransferase, Alanine aminotransferase, Lactate dehydrogenase, C-reactive protein, Fibrinogen, Troponin T, arterial blood gas (pH, PaO2, PaCO2, SaO2). Creatinine was not included, as we already considered chronic renal insufficiency as a variable.

2.4 X-Ray analysis and quantification
All Chest X-Rays (CXR) were acquired in the posteroanterior (PA) + laterolateral projections on a fixed radiographic machine, or in the anteroposterior (AP) projection on a portable radiographic unit, according to our standard acquisition protocols.

Two radiologists (MC, a radiologist with 9 years of experience; MO, a radiologist with 7 years of experience) in consensus assessed for each X-Ray: 1) the presence of lung abnormalities, described as consolidation, ground-glass opacities (GGO), or nodules, according to the Fleischner Society glossary of terms [13] (Figure 1); 2) their distribution, classified into (i) “peripheral”, “central”, or “both”; and into (ii) “unilateral” or “bilateral”. The presence of pleural effusion was recorded.

A radiographic severity score, according to Wong et al [14], was independently assigned by two radiologists (MP, radiologist with 7 years of experience; GO, radiologist with 25 years of experience), depending on the extent of involvement by consolidation or GGO (0 = no involvement; 1 = <25%; 2 = 25-50%; 3 = 50-75%; 4 = >75% involvement), for each lung, with a maximum score of 8 for CXR. Some examples are provided in Figure 2. Interobserver agreement was evaluated.

2.5 Statistical analysis

Values were checked with a one-sample Kolmogorov–Smirnov test for normality. Interobserver agreement was assessed through Cohen’s k correlation coefficient. Kruskal-Wallis H test and Mann-Whitney U test were used to evaluate differences between independent groups. Chi-Square test or Fisher's exact test were used to determine significant relationships between categorical variables. Correlations between values were evaluated through Spearman’s Correlation Coefficient: among redundant variables (Spearman coefficient > .80). The relationship between fatal outcome with CXR severity score, radiological features, and clinical and laboratory parameters was investigated fitting a logistic
regression model. p<.05 was regarded as statistically significant. In order to avoid redundancy, we selected between all variables with p <.05 the independent variables (Spearman’s K <0.8) and the most informative among redundant variables, based on ROC analysis. A model was built with the variables thus selected by a backward stepwise model. A chi-squared automatic interaction detection (CHAID) decision tree analysis with CXR score as the user-specified first level was used to detect the fatal outcome. Statistical analysis was performed using SPSS (IBM SPSS Statistics, Version 26.0, IBM Corp).

3. Results

3.1 Patients

According to our exclusion criteria, 246 patients were enrolled. Most patients were men (170/246, 69%), with a mean age of 63 years; 154/246 patients (62%) have at least one chronic disease (Table 1). Upon admission, most patients had fever (234/246; 95%) and cough (148/246; 60%); C-reactive protein levels were increased in the 216/246 (88%) of patients (Table 2).

Most of the patients received a combination of antibiotics and antiviral therapy (152/246 patients, 62%). Patients’ treatments are listed in Table 3.

3.2 X-Ray analysis and quantification

156/246 (63%) CXR were executed in the posteroanterior projection on a portable X-Ray unit. 218/246 (88.6%) of CXR showed abnormalities. Most patients (222/246, 90.2%) showed GGO, with bilateral (158/246, 64.2%) and peripheral (114/246, 46.3%) distribution. The mean radiographic severity score was 3 ± 2. Interobserver agreement was excellent (Cohen’s K coefficient: 0.901). Overall imaging findings are listed in Table 4.

3.3 Fatal outcome prediction

3.3.1 Univariate analysis
The correlation at the univariate analysis of the analyzed variables with fatal outcome is listed in Table 1, 2, 4.

We observed that different variables significantly correlated with the outcome: sex (p=.001), and age (<.001), various comorbidities, assumption of ACEi (<.001), and days of hospitalization (<.001).

Analyzing symptoms upon admission, only dyspnea correlated with mortality (p=.001); fever did not correlate (p=.336), but the days of fever did (<.001).

Among blood tests, C-reactive protein, D-dimer, and Fibrinogen were significantly correlated with the outcome (p=0.001).

At CXR, GGO with peripheral distribution, consolidation, pleural effusion, and the severity score showed a significant correlation with fatal outcome (p< .001)

3.3.2 Multivariate analysis

We confirmed the significant correlation with fatal outcome of age (p<.001, Odds Radio [OR]: 1.206; 95% confidence interval [CI]: 1.12-1.29), diabetes (p<.001, OR: 18.890; 95% CI: 2.9-123.0) and chronic obstructive pulmonary disease (p<.001, OR: 7.368; 95%CI: 1.44-37.60); among radiological features, consolidation (p=.004, OR: 5.472, 95% CI: 1.698-17.635) and peripheral GGO (p=.0.14, OR: 4.208; 95% CI: 1.343-13.192) were significantly correlated with fatal outcome at multivariate analysis. See Table 5 for results.

Lymphocytes (p=.726, OR: .634; 95% CI: .050-8.109), Troponin T (p=. 164; OR: 1.698; 95% CI: .805-3.581), C-reactive protein (p=.901, OR:1.120; 95% CI: .187-6.722), D-dimer (p=.292, OR:2.883; 95% CI: .403-20.632), and Fibrinogen (p=.476, OR: 1.946; 95% CI: .312-12.118) did not show statistically significant correlation with the outcome at multivariate analysis.

Multivariate analysis using the chi-squared automatic interaction detection (CHAID) method showed that the two most significant variables in predicting a fatal outcome were the age of
the patient and the presence of consolidation. Mortality was 59% in patients >66 years old, and 5% in patients younger than that; in the latter group mortality was 11% in patients presenting with consolidation, and 2% in those without it.

4. Discussion

In our retrospective study, we observed that the fatal outcome had a significant correlation with sex, age, various comorbidities, the assumption of ACEi, and days of hospitalization (<.001). The only symptom upon admission with a significant correlation was dyspnea, whereas, among blood tests, mainly Troponin T, C-reactive protein, D-dimer, and Fibrinogen significantly correlated with the outcome. Regarding radiological variables, consolidation, peripheral GGO, pleural effusion, and the severity score showed a significant correlation.

At the logistic regression model, only age, diabetes, chronic obstructive pulmonary disease, peripheral GGO, consolidation, showed significance as independent risk factors for fatal outcome in COVID-19 infection.

Understanding of the new coronavirus SARS-CoV-2 and COVID-19 is still evolving.

Disease severity varies broadly, with an estimated 81% confirmed cases showing only mild disease, 14% severe pneumonia (defined as dyspnea, hypoxia, or >50% lung involvement on imaging within 24-48h), and 5% critical disease (defined as respiratory failure, shock, or multiorgan failure) [2,15]. The case-fatality rate ranged from 0.7 to 14 %, varying by location, the intensity of transmission, and the time of infection. The risk factors of mortality are still unclear: most of the fatal cases were observed in older patients or patients with underlying medical comorbidities [15-20], but other clinical factors still need to be identified.

In line with our results, a study on 150 patients in Wuhan, China [31], demonstrated a significant difference in age between the dead and discharged patients (p < 0.001), but no difference in the sex ratio. Moreover, 63% of patients in the death group and 41% of patients in the discharge group had underlying diseases, with statistically significant differences;
especially patients with cardiovascular diseases showed a significantly increased risk of death (p < 0.001). Significant differences between the two groups were also observed in white blood cell counts, absolute values of lymphocytes, platelets, albumin, total bilirubin, blood urea nitrogen, blood creatinine, myoglobin, cardiac troponin, C-reactive protein, and interleukin-6 between; however, the regression analysis was not performed to assess their role as independent risk factors.

Low white cells and platelet count, high D-dimer values, and high pro-thrombin time showed a correlation with mortality [8,20]. Significantly higher levels of aspartate aminotransferase, urea, creatinine, creatinine kinase, and lactate dehydrogenase were found in dead patients than in survivors [8,21,22].

In our study, no blood tests showed significance as an independent risk factor of mortality. Other authors considered different variables as predictors of outcome in COVID-19 patients. Chen et al [4] applied a severity score for other types of viral pneumonia, called “MuLBSTA score” [23] to predict the risk of mortality in COVID-19 patients: this score system includes multilobar infiltration at imaging, lymphopenia, bacterial co-infection, smoking history (acute or previous), hypertension, and age (≥60 years). The authors observed that in their population of 99 cases in Wuhan, China, the characteristics of patients who died were in line with the MuLBSTA score, but claimed the need of further studies to assess the applicability of this score in the prediction of the risk of mortality in COVID-19 patients. The evidence of the age as a risk factor for unfavorable outcome is in line with our results.

In a retrospective cohort of 1,590 hospitalized patients with COVID-19 throughout China [24], age > 65 years, and a history of coronary heart disease and cerebrovascular disease were significantly associated with non-survival of the patients; the presence of dyspnea, and high procalcitonin (> 0.5 ng/mL), and aspartate aminotransferase level (> 40 U/L) proved to be independent risk factors of fatal outcome.
From a radiological point of view, the main radiological characteristics of COVID-19 pneumonia are the alveolar disease represented by GGO (40-91%), with bilateral distribution (28-91%), and a prevalent involvement of peripheral areas (22-71%). This triad seems to be more common in the middle stages of the disease [25, 26]. These findings were confirmed to be the most common presentation in our study and a peripheral presentation was also found to be correlated to a fatal outcome at univariate analysis; this result, confirmed at multivariate analysis, suggests an underlying mechanism different from simple alveolar damage may link GGO and mortality, as shown in a work by Lang et al [27].

The evidence at the univariate analysis of a significant correlation of pleural effusion with the final outcome is in line with the results previously reported by Li et al, who suggested the role of this imaging finding as an index of severe disease [28]. Pan et al [25] and Shi et al [26] reported that consolidation seems to be more common in the later stages; the correlation found in our work at univariate analysis between consolidation and the fatal outcome can be thought to be due to patients presenting in a later stage of the disease having a worse outcome than patient presenting sooner. Nevertheless, multivariate analysis showed consolidation to be an independent predictor of mortality.

In our study a significant correlation was found between a fatal outcome and the CXR severity score: a similar result was obtained in a retrospective study on 100 hospitalized patients with COVID-19 infection by Borghesi et al, in which the quantitative analysis of chest X-Ray, based on the type of lung abnormalities, significantly correlated with the final outcome, with severity score higher (p≤.002) in patients who died than those discharged [29]. The value of CXR severity score upon admission had also been proved in middle-aged patients, demonstrating that a severity score CXR score ≥3 was an independent predictor for intubation, and was higher in patients who died than in survivors, even if without statistically significant difference [30].
In our case series, most of the patients were treated with hydroxychloroquine, an analog of chloroquine with a better safety profile, and fewer drug interactions, that showed in vitro antiviral activity against SARS-CoV2 [31]. As the epicenter of COVID-19 shifted from China to Europe, the use of hydroxychloroquine was recommended also by European authors as a possible prophylaxis and curative treatment for COVID-19 [32,33], therefore we adopted its use in our COVID-19 treatments. The effective benefits form this treatment still remains unclear, [34], and its use is now limited to clinical studies [35].

This study has different limitations: first of all, related to the retrospective nature of this study. This is a single-center study with a relatively limited number of patients. We excluded many patients because even if the reported symptoms were suspected for COVID-19 infection, the diagnosis was not confirmed by the RT-PCR, moreover, we excluded patients with data missing due to the retrospective nature of the study, to the transferal to and from other hospitals, to the longtime of hospitalization. Even if many variables were included, according to our routine clinical practice, other variables could be assessed (i.e. the smoking history, other laboratory tests…); moreover, other possible clinical outcomes, as the need for mechanical ventilation, can be considered.

Another limitation was that the therapy was inhomogeneous due to the absence of specific treatment guidelines at the time of the study; however, the clinical benefits of most treatments tested in COVID-19 patients remain controversial. Due to the complexity of the current clinical situation, studies including large case series and different variables are desirable and needed.
5. Conclusion

Predictors of a fatal outcome in COVID-19 cases included age, the presence of underlying diseases (diabetes and Chronic Obstructive Pulmonary Disease), and the radiological evidence of peripheral GGO and consolidation.

We identified some variables associated with unfavorable outcome in patients affected by COVID-19 pneumonia. The presence of risky variables upon patients’ admission can help better management of patients and the right allocation of the available healthcare resources.
Figure 1. Examples of CXR abnormalities

**Figure 1a:** Chest X-Ray showing a focal GGO involving the middle-upper fields of the right lung (frame).

**Figure 1b:** Chest X-Ray showing area of consolidation in the lower right fields (frame).

GGO are recognizable in the lower fields of the left lung.
Figure 2. Examples of CXR severity score assignment

Figure 2a: CXR showing focal bilateral GGO in the lower fields (frames). On both left and right lung, the involvement was <25%, therefore the CXR severity score assigned was 1 for each lung, with a global score of 2.

Figure 2b: CXR showing bilateral parenchymal opacities (frames): a huge area of consolidation in the middle-lower left fields with contextual air bronchogram, while a focal area of ground-glass opacity is recognizable in the upper fields of the left lung; the extension on the left side was >50% (score 3), whereas the involvement on the right side was <25% (score 1); therefore, the overall score was 3 + 1 = 4.

Figure 2c: CXR showing bilateral involvement, with mixed areas of GGO and consolidation (frames) involving all the lung fields. On both left and right lung, the involvement was >75% (score 4); therefore, the global score was 4 + 4 = 8.
Table 1

Anagraphic data of patients, comorbidities, assumption of Angiotensin-converting enzyme inhibitors (ACE) inhibitors, days of hospitalization. In the last column, correlation of these characteristics with fatal outcome.

|                  | Patients number/total (%) | Statistical correlation with fatal outcome (p) |
|------------------|---------------------------|-----------------------------------------------|
| **Sex**          |                           |                                               |
| Male             | 170/246 (69%)             | .001 (Pearson X2 test)                        |
| Female           | 76/246 (31%)              |                                               |
| **Age**          |                           |                                               |
| Mean age         | 63±16.25                  |                                               |
| Age range        | 30-95                     |                                               |
| **Comorbidities**|                           |                                               |
| Patients         |                           | Pearson X2 test (p)                           |
| Condition                                      | Count/Total | Percentage  | P-value |
|-----------------------------------------------|-------------|-------------|---------|
| Diabetes                                      | 30/246      | (12.2%)     | < .001  |
| Arterial hypertension                         | 112/246     | (45.5%)     | .274    |
| Chronic obstructive pulmonary disease         | 26/246 (10.5%) |            | .085    |
| Asthma                                        | 10/246      | (4%)        | < .001  |
| Cardiovascular disease                        | 56/246      | (22.7%)     | < .001  |
| Previous episodes of cardiac failure          | 6/246 (2.4%) |             | < .001  |
| Atrial fibrillation                           | 18/346 (7.3%) |            | .776    |
| Stroke                                        | 10/246 (4%) |             | .305    |
| Dementia                                      | 6/246 (2.4%) |             | .428    |
| Obesity                                       | 12/246      | (4.8%)      | .266    |
| Condition                                      | Count | Percentage | p-value |
|------------------------------------------------|-------|------------|---------|
| Chronic renal insufficiency                   | 10/246| 4%         | <.001   |
| Malignancy                                    | 26/246| 10.5%      | .237    |
| HIV infection                                 | 2/246 | 0.8%       | .655    |
| Assumption of Angiotensin-converting enzyme inhibitors (ACE) inhibitors | 28/246| 11.4%      | <.001   |
| Days of hospitalization                       | 14.51 | 11.5%      | <.001   (Mann-Whitney U-test) |
Table 2

Patients’ signs, symptoms, and laboratory tests and their correlation with the fatal outcome.

NR= Normal Range

| Sign and Symptoms                  | Patients Number/total (%) | Statistical correlation with fatal outcome (p) |
|------------------------------------|---------------------------|---------------------------------------------|
| Cough                              | 148/246 (60.1%)           | .140 (Pearson X2 test)                      |
| Dyspnea                            | 120/246 (48.8%)           | .001 (Pearson X2 test)                      |
| Hemoptysis                         | 2/246 (0.8%)              | .656 (Pearson X2 test)                      |
| Chest pain                         | 12/246 (4.9%)             | .336 (Pearson X2 test)                      |
| Cutaneous rash                     | 2/246 (0.8%)              | .656 (Pearson X2 test)                      |
| Gastrointestinal symptoms          | 52/246 (21.14%)           | .722 (Pearson X2 test)                      |
| Conjunctivitis                     | 4/246 (1.63%)             | .527 (Pearson X2 test)                      |
| Fever                              | 234/246 (95.1%)           | .336 (Pearson X2 test)                      |
| Days of fever                      | 6.7±6 (3.5%)              | <.001 (Pearson X2 test)                     |
| Temperature                        | 37.9±0.8° C               | .432 (Mann-Whitney U-test)                  |
| Oxygen saturation                  | 91.5±7.7                  | <.001 (Mann-Whitney U-test)                 |
| **Blood tests**                    |                           | **p (Mann-Whitney U-test)**                 |
| Leukocytes                         | 7.3±3.9 10⁹/L             | .023                                         |
| Parameter                  | Value                           | P-value |
|----------------------------|---------------------------------|---------|
| Neutrophils                | 5.4±3.9 10⁹/L (NR 1.91-6.23 10⁹/L) | .126    |
| Monomorphous %            | 24.87±13 %                      | .004    |
| Polymorphus %             | 75.15±12.9 %                    | .004    |
| Lymphocytes               | 1.4±1.4 x10⁹/L (NR 1.13-3.37x10⁹/L) | .028    |
| Platelets                 | 227±111x10⁹/L (NR. 169-359 10⁹/L) | .463    |
| Erythrocytes              | 4.7±0.8x10¹²/L (NR 4.13-5.15*10¹²/L) | .084    |
| D-dimer                   | 1532±5600 ng/mL (NR 250-500 ng/mL) | <.001   |
| Aspartate aminotransferase| 54.1±38.2 U/L (NR 10-35 U/L)   | .290    |
| Alanine aminotransferase  | 44.6±41 U/L (NR. 10-33 U/L)     | .455    |
| Lactate dehydrogenase     | 353.6±148.9 U/L (NR 135-225 U/L) | .023    |
| C-reactive protein        | 99.8±94.3 mg/L (NR 0-5 mg/L)    | <.001   |
| Test                  | Value                          | P-Value |
|----------------------|-------------------------------|---------|
| Fibrinogen           | 633.86±88.82 (V.N. 270-470 mg/dL) | .007    |
| Troponin T           | 32.03±38.29 (V.N. 0-14 ng/L)   | .001    |
| Arterial blood gas   |                               |         |
| pH                   | 7.46±0.056                    | .381    |
| PaO2                 | 63.68±18.85                   | .620    |
| PaCO2                | 33.40±8.94                    | .951    |
| SaO2                 | 91.16±11.29                   | .443    |
Table 3

Patients treatment during hospitalization.

| Treatment                                      | Patients number/total (%) |
|------------------------------------------------|---------------------------|
| Non invasive ventilation                      | 86/246 (34.9%)            |
| Invasive ventilation                          | 26/246 (10.5%)            |
| Hydroxychloroquine                            | 206/246 (83.7%)           |
| Antiviral treatment (Lopinavir/Ritonavir)     | 166/246 (67.5%)           |
| Antibiotic treatment (Azithromycin)           | 218/246 (88.6%)           |
| Tocilizumab                                    | 46/246 (18.7%)            |
| Paracetamol                                    | 148/246 (60.1%)           |
| Dexamethasone                                  | 88 (35.7%)                |
| Methylprednisolone                             | 16 (6.5%)                 |
Table 4

Radiographic findings and their distribution, and radiographic severity score in our patient population and correlation with the fatal outcome.

GGO=ground glass opacities

| Patients number/total (%) | Statistical correlation with fatal outcome (p) |
|--------------------------|-----------------------------------------------|
| **Presence of X-Ray abnormalities** | 218/246 (88.6%) | < .001 (Pearson X2 test) |
| **Radiographic findings** | Pearson X2 test |
| GGO | 222/246 (90.2%) | < .001 |
| Consolidation | 106/246 (43%) | < .001 |
| Nodules | 0/246 (0%) | |
| Pleural effusion | 26/246 (10.5%) | < .001 |
| **Distribution** | < .001 (Pearson X2 test) |
| Peripheral | 114/246 (46.3%) | |
| Location          | Count   | Percentage |
|-------------------|---------|------------|
| Central           | 30/246  | 12.2%      |
| Peripheral+central| 80/246  | 32.5%      |
| **Side**          |         | < .001 (Pearson X2 test) |
| Unilateral        | 66/246  | 26.8%      |
| Bilateral         | 158/246 | 64.2%      |
| **Severity Score**| 3.28±2.02 | < .001 (Pearson X2 test) |
Table 5

Results of the multivariate analysis

C.I.=confidence interval

GGO=ground glass opacities

COPD=Chronic Obstructive Pulmonary Disease

|                    | B    | S.E. | Wald | gl | Sign. | Exp(B) | 95% C.I. | EXP(B) | Inferior | Superior |
|--------------------|------|------|------|----|-------|--------|----------|--------|----------|----------|
| Peripheral GGO     | 1.437| 0.583| 6.077| 1  | 0.014 | 4.208  | 1.343    | 13.192 |
| Consolidation      | 1.700| 0.597| 8.105| 1  | 0.004 | 5.472  | 1.698    | 17.635 |
| Diabetes           | 2.939| 0.956| 9.449| 1  | 0.002 | 18.890 | 2.901    | 123.016|
| COPD               | 1.997| 0.832| 5.769| 1  | 0.016 | 7.368  | 1.444    | 37.599 |
| Age                | 0.187| 0.034| 29.713| 1 | 0.000 | 1.206  | 1.128    | 1.290  |
| Constant           | -17.063| 2.893| 34.787| 1 | 0.000 | 0.000  | 0.000    | 0.000  |
References

[1] Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol 2020;92(4):401-402.

[2] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020. doi:10.1016/S0140-6736(20)30183-5

[3] WHO Coronavirus disease (COVID-19) Dashboard. https://covid19.who.int/

[4] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395: 507–13. doi:10.1016/S0140-6736(20)30211-7.

[5] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585.

[6] Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020;63(5):706–711. doi:10.1007/s11427-020-1661-4.

[7] Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. 2020;94:154-155. doi:10.1016/j.ijid.2020.03.020.

[8] Zhang L, Yan X, Fan Q, Liu H, Liu X, Zhang Z. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020;10.1111/jth.14859. doi:10.1111/jth.14859.

[9] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. doi:10.1056/NEJMoa2002032.
[10] Epidemiology for Public Health. Istituto Superiore di Sanità. Characteristics of COVID-19 patients dying in Italy. https://www.epicentro.iss.it/coronavirus/sars-cov-2-decessi-italia. Accessed on July 22th, 2020.

[11] Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273. doi:10.1038/s41586-020-2012-7.

[12] Patel AB, Verma A. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? JAMA. 2020;10.1001/jama.2020.4812. doi:10.1001/jama.2020.4812.

[13] Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner Society: Glossary of terms for thoracic imaging. Radiology. 2008;246(3):697-722. doi:10.1148/radiol.2462070712.

[14] Wong HYF, Lam HYS, Fong AH, Leung ST, Chin TW, Lo CSY et al. Frequency and Distribution of Chest Radiographic Findings in COVID-19 Positive Patients. Radiology. 2019;201160. doi:10.1148/radiol.2020201160.

[15] Wu Z, McGoogan J. M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA. 2020;323(13):1239–1242. doi:10.1001/jama.2020.2648.

[16] Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) and coronavirus disease–2019 (COVID–19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;105924. doi:10.1016/j.ijantimicag.2020.105924.

[17] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1038. doi:10.1016/S0140-6736(20)30566-3.
[18] Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;S0091-6749(20)30495-4. doi:10.1016/j.jaci.2020.04.006;

[19] Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020;55(5):2000524. Published 2020 May 7. doi:10.1183/13993003.00524-2020

[20] Wang L, He W, Yu X, Hu D, Bao M, Liu H et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infection. pii: S0163-4453(20)30146-8. doi: 10.1016/j.jinf.2020.03.019.

[21] Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther 2000;5:33. doi: 10.1038/s41392-020-0148-4.

[22] Yang Z, Shi J, He Z, Lü Y, Xu Q, Ye C et al. Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients. Aging (Albany NY). 2020;12(7):6037-48. doi: 10.18632/aging.102999.

[23] Guo L, Wei D, Zhang X, et al. Clinical Features Predicting Mortality Risk in Patients With Viral Pneumonia: The MuLBSTA Score. Front Microbiol. 2019 Dec 3;10:2752. doi: 10.3389/fmicb.2019.02752.

[24] Chen R, Liang W, Jiang M, Jiang M, Guan W, Zhan C et al. Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. Chest Journal. 2020;20-0849. doi: 10.1016/j.chest.2020.04.010.

[25] Pan F, Ye T, Sun P, Gui S, Liang B, Li L et al. Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. Radiology. 2020;200370. doi:10.1148/radiol.2020200370.

[26] Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J et al. Radiological findings from 81
patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. The Lancet Infectious Diseases. 2020;20:425–34. doi:10.1016/s1473-3099(20)30086-4.

[27] Lang M, Som A, Mendoza DP, Flores EJ, Reid N, Carey D et al. Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT. Lancet Infect Dis. 2020;S1473-3099(20)30367-4. doi:10.1016/S1473-3099(20)30367-4.

[2-8] Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, Li C. The Clinical and Chest CT Features Associated with Severe and Critical COVID-19 Pneumonia. Invest Radiol. 2020;55(6):327-331. doi: 10.1097/RLI.0000000000000672.

[29] Borghesi A, Maroldi R. COVID-19 outbreak in Italy: experimental chest X-ray scoring system for quantifying and monitoring disease progression. Radiol Med. 2020. doi:10.1007/s11547-020-01200-3.

[30] Toussie D, Voutsinas N, Finkelstein M, et al. Clinical and Chest Radiography Features Determine Patient Outcomes In Young and Middle Age Adults with COVID-19. Radiology. 2020;201754. doi:10.1148/radiol.2020201754

[31] Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. Published 2020 Mar 18. doi:10.1038/s41421-020-0156-0

[32] Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020;55(3):105923. doi:10.1016/j.ijantimicag.2020.105923

[33] Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55(4):105932. doi:10.1016/j.ijantimicag.2020.105932

[34] Funck-Brentano C, Salem JE. Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous? Lancet. 2020;S0140-6736(20)31174-0. doi:10.1016/S0140-6736(20)31174-0
[35] Agenzia Italiana del Farmaco https://www.aifa.gov.it/web/guest/-/aifa-sospende-l'autorizzazione-all-utilizzo-di-idrossiclorochina-per-il-trattamento-del-covid-19-al-di-fuori-degli-studi-clinici.